1-20 of 25
Axel Haupt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept

Free
SHOBHA N. BHATTACHAR, LAI-SAN THAM, BETH TIDEMANN-MILLER, DANIEL A. BRIERE, HONGCHANG QU, AXEL HAUPT, EDWARD J. PRATT, KIEREN J. MATHER
Journal: Diabetes
Diabetes 2025;74(Supplement_1):882-P
https://doi.org/10.2337/db25-882-P
Published: 20 June 2025
View article titled, 882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept
Meeting Abstracts

754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials

Free
HIDDO L. HEERSPINK, ZEQING LU, YU DU, KEVIN L. DUFFIN, TAMER COSKUN, AXEL HAUPT, MARK L. HARTMAN
Journal: Diabetes
Diabetes 2024;73(Supplement_1):754-P
https://doi.org/10.2337/db24-754-P
Published: 14 June 2024
View article titled, 754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials
Meeting Abstracts

263-OR: Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain

Free
OWEN CARMICHAEL, CORBY K. MARTIN, ROBERT V. CONSIDINE, DAVID A. KAREKEN, SUSAN CARNELL, ULRIKE DYDAK, RICHARD D. MATTES, DAVID SCOTT, DIANA O. SVALDI, HIROSHI NISHIYAMA, LUKASZ BIERNAT, AXEL HAUPT, ZVONKO MILICEVIC, SERGEY SHCHERBININ, TAMER COSKUN
Journal: Diabetes
Diabetes 2024;73(Supplement_1):263-OR
https://doi.org/10.2337/db24-263-OR
Published: 14 June 2024
View article titled, 263-OR: Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain
Meeting Abstracts

117-OR: Effects of Triple-Hormone Receptor Agonist Retatrutide on Lipid Profiling in Participants with Obesity

Free
VALENTINA PIRRO, MACKENZIE J. PEARSON, YANZHU LIN, MARK L. HARTMAN, KENNETH D. ROTH, KEVIN L. DUFFIN, JILL WILLENCY, AXEL HAUPT, GIACOMO RUOTOLO
Journal: Diabetes
Diabetes 2024;73(Supplement_1):117-OR
https://doi.org/10.2337/db24-117-OR
Published: 14 June 2024
View article titled, 117-OR: Effects of Triple-Hormone Receptor Agonist Retatrutide on Lipid Profiling in Participants with Obesity
Meeting Abstracts

761-P: Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes

Free
JUAN P. FRIAS, STANLEY H. HSIA, SARAH EYDE, RONG LIU, XIAOSU MA, MANIGE KONIG, CHRISTOF M. KAZDA, EDWARD J. PRATT, KIEREN J. MATHER, AXEL HAUPT, DEBORAH A. ROBINS
Journal: Diabetes
Diabetes 2023;72(Supplement_1):761-P
https://doi.org/10.2337/db23-761-P
Published: 25 June 2023
View article titled, 761-P: Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes
Meeting Abstracts

52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study

Free
SEAN WHARTON, THOMAS BLEVINS, LISA B. CONNERY, JULIO ROSENSTOCK, SOHINI RAHA, KIEREN J. MATHER, AXEL HAUPT, DEBORAH A. ROBINS, EDWARD J. PRATT, CHRISTOF M. KAZDA, MANIGE KONIG
Journal: Diabetes
Diabetes 2023;72(Supplement_1):52-OR
https://doi.org/10.2337/db23-52-OR
Published: 23 June 2023
View article titled, 52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study
Meeting Abstracts

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Free
THOMAS PIEBER, EVA SVEHLIKOVA, SHWETA URVA, AXEL HAUPT, CHUNMEI ZHOU, TAMER COSKUN, ZVONKO MILICEVIC, EDWARD J. PRATT
Journal: Diabetes
Diabetes 2023;72(Supplement_1):129-OR
https://doi.org/10.2337/db23-129-OR
Published: 20 June 2023
View article titled, 129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes
Meeting Abstracts

128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity

Free
CORBY K. MARTIN, ERIC RAVUSSIN, GUILLERMO SANCHEZ-DELGADO, HIROSHI NISHIYAMA, JING LI, SHWETA URVA, EDWARD J. PRATT, ZVONKO MILICEVIC, AXEL HAUPT, TAMER COSKUN
Journal: Diabetes
Diabetes 2023;72(Supplement_1):128-OR
https://doi.org/10.2337/db23-128-OR
Published: 20 June 2023
View article titled, 128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity
Meeting Abstracts

811-P: Initiation of Once-Weekly (QW) Basal Insulin Fc (BIF) in Three Patient Populations in Phase 2 Studies Using a One-Time Loading Dose (LD) Minimizes Transient Hyperglycemia and Is Not Associated with Excess Hypoglycemia Risk vs. Degludec

Free
JULIANA M. BUE-VALLESKEY, CHRISTOF M. KAZDA, QIANYI ZHANG, AXEL HAUPT, DOMINIK DAHL, JUAN P. FRIAS
Journal: Diabetes
Diabetes 2023;72(Supplement_1):811-P
https://doi.org/10.2337/db23-811-P
Published: 20 June 2023
View article titled, 811-P: Initiation of Once-Weekly (QW) Basal Insulin Fc (BIF) in Three Patient Populations in Phase 2 Studies Using a One-Time Loading Dose (LD) Minimizes Transient Hyperglycemia and Is Not Associated with Excess Hypoglycemia Risk vs. Degludec
Meeting Abstracts

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

Free
FILIP K. KNOP, SHWETA URVA, MALLIKARJUNA RETTIGANTI, CHARLES BENSON, WILLIAM ROELL, KIEREN J. MATHER, AXEL HAUPT, EDWARD J. PRATT
Journal: Diabetes
Diabetes 2023;72(Supplement_1):56-OR
https://doi.org/10.2337/db23-56-OR
Published: 20 June 2023
View article titled, 56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting
Meeting Abstracts

127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity

Free
ERIC RAVUSSIN, GUILLERMO SANCHEZ-DELGADO, CORBY K. MARTIN, HIROSHI NISHIYAMA, JING LI, SHWETA URVA, EDWARD J. PRATT, TAMER COSKUN, ZVONKO MILICEVIC, AXEL HAUPT
Journal: Diabetes
Diabetes 2023;72(Supplement_1):127-OR
https://doi.org/10.2337/db23-127-OR
Published: 20 June 2023
View article titled, 127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity
Meeting Abstracts

806-P: Once Weekly (QW) Basal Insulin Fc (BIF) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in Three Patient Populations Studied during Phase 2—Clinical Insights from CGM Assessments

Free
CHRISTOF M. KAZDA, JULIANA M. BUE-VALLESKEY, QIANYI ZHANG, AXEL HAUPT, JUAN P. FRIAS, DOMINIK DAHL
Journal: Diabetes
Diabetes 2023;72(Supplement_1):806-P
https://doi.org/10.2337/db23-806-P
Published: 20 June 2023
View article titled, 806-P: Once Weekly (QW) Basal Insulin Fc (BIF) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in Three Patient Populations Studied during Phase 2—Clinical Insights from CGM Assessments
Meeting Abstracts

318-OR: Tirzepatide Reduces Albuminuria in Patients with T2D—Post Hoc Pooled Analysis of SURPASS 1–5

Free
HIDDO L. HEERSPINK, KATHERINE R. TUTTLE, IMRE PAVO, AXEL HAUPT, ZHENGYU YANG, RUSSELL WIESE, ANDREA HEMMINGWAY, DAVID CHERNEY, NAVEED SATTAR
Journal: Diabetes
Diabetes 2023;72(Supplement_1):318-OR
https://doi.org/10.2337/db23-318-OR
Published: 20 June 2023
View article titled, 318-OR: Tirzepatide Reduces Albuminuria in Patients with T2D—Post Hoc Pooled Analysis of SURPASS 1–5
Meeting Abstracts

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

Free
KIEREN J. MATHER, ANDREA MARI, JING LI, TIM HEISE, J. HANS DE VRIES, SHWETA URVA, TAMER COSKUN, ZVONKO MILICEVIC, AXEL HAUPT, MELISSA K. THOMAS
Journal: Diabetes
Diabetes 2022;71(Supplement_1):714-P
https://doi.org/10.2337/db22-714-P
Published: 01 June 2022
View article titled, 714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism
Meeting Abstracts

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

Free
SHWETA URVA, MEI TENG LOH, TAMER COSKUN, YU DU, CHARLES BENSON, CORINA LOGHIN, AXEL HAUPT, ZVONKO MILICEVIC
Journal: Diabetes
Diabetes 2022;71(Supplement_1):340-OR
https://doi.org/10.2337/db22-340-OR
Published: 01 June 2022
View article titled, 340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment
Meeting Abstracts

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

Free
TIM HEISE, J. HANS DE VRIES, TAMER COSKUN, SHWETA URVA, JING LI, EDWARD J. PRATT, MELISSA K. THOMAS, KIEREN J. MATHER, JULIA P. DUNN, AXEL HAUPT, ZVONKO MILICEVIC
Journal: Diabetes
Diabetes 2022;71(Supplement_1):338-OR
https://doi.org/10.2337/db22-338-OR
Published: 01 June 2022
View article titled, 338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D
Meeting Abstracts

17-OR: ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4

Free
HIDDO L. HEERSPINK, NAVEED SATTAR, IMRE PAVO, AXEL HAUPT, KEVIN L. DUFFIN, ZHENGYU YANG, RUSSELL WIESE, KATHERINE R. TUTTLE, DAVID CHERNEY
Journal: Diabetes
Diabetes 2022;71(Supplement_1):17-OR
https://doi.org/10.2337/db22-17-OR
Published: 01 June 2022
View article titled, 17-OR: ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4
Meeting Abstracts

215-OR: Once Weekly (QW) Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily (QD) Insulin Degludec (DEG) in Insulin-Naïve Patients with Type 2 Diabetes (T2D)

Free
JULIANA M. BUE-VALLESKEY, CHRISTOF M. KAZDA, CHENCHEN MA, JENNY CHIEN, QIANYI ZHANG, EMMANUEL CHIGUTSA, WILLIAM LANDSCHULZ, JENNIFER SWAN, AXEL HAUPT, JUAN PABLO FRIAS
Journal: Diabetes
Diabetes 2022;71(Supplement_1):215-OR
https://doi.org/10.2337/db22-215-OR
Published: 01 June 2022
View article titled, 215-OR: Once Weekly (QW) Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily (QD) Insulin Degludec (DEG) in Insulin-Naïve Patients with Type 2 Diabetes (T2D)
Meeting Abstracts

192-OR: Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study

Free
CHRISTOF M. KAZDA, JENNY CHIEN, QIANYI ZHANG, EMMANUEL CHIGUTSA, WILLIAM LANDSCHULZ, PAULA WULLENWEBER, AXEL HAUPT, JUAN P. FRIAS
Journal: Diabetes
Diabetes 2021;70(Supplement_1):192-OR
https://doi.org/10.2337/db21-192-OR
Published: 01 June 2021
View article titled, 192-OR: Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study
Meeting Abstracts

134-OR: Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D

Free
MARK L. HARTMAN, ARUN SANYAL, ROHIT LOOMBA, JONATHAN M. WILSON, ROSS BRAY, AMIR NIKOOIENEJAD, KEVIN L. DUFFIN, DEBORAH A. ROBINS, AXEL HAUPT
Journal: Diabetes
Diabetes 2019;68(Supplement_1):134-OR
https://doi.org/10.2337/db19-134-OR
Published: 01 June 2019
View article titled, 134-OR: Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D